NCT06513884 2025-06-22A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal CancerHookipa Biotech GmbHPhase 2/3 Withdrawn
NCT05893888 2025-06-15Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell CarcinomaPrivo TechnologiesPhase 2/3 Recruiting40 enrolled
NCT06719479 2024-12-05A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).SUNHO(China)BioPharmaceutical CO., Ltd.Phase 2/3 Not yet recruiting60 enrolled
NCT04969861 2023-01-12BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)Nektar TherapeuticsPhase 2/3 Terminated1 enrolled 6 charts
NCT04129320 2022-02-08Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckMacroGenicsPhase 2/3 Withdrawn
NCT00412776 2015-12-23Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck CancerSesen Bio, Inc.Phase 2/3 Terminated165 enrolled